Patients with chronic renal and heart failure present with hypertension and widespread vasoconstriction, respectively. Although systemic release of nitric oxide (NO) may be elevated in both pathological syndromes, enhanced production of NO fails to overcome endothelial dysfunction. Plasma concentrations of L-arginine, a cationic amino acid precursor for NO synthesis, are reduced whilst levels G of the endogenous L-arginine analogues, asymmetric and symmetric dimethyl arginine and N -monomethyl-L-arginine, seem to be 1 1 elevated. We have reported that transport of L-arginine via the cationic amino acid transporters y / CAT and / or y L are up-regulated in erythrocytes, peripheral blood mononuclear cells and platelets from both patients with either chronic renal or heart failure. A possible explanation why NO serves as a failing counter-regulatory mechanism in both these pathologies is that availability of L-arginine for NO production is reduced despite the observed increase in membrane transport. This review examines the mechanisms underlying alterations in NO production in chronic renal and heart failure, and the possible role of L-arginine transport in vascular and platelet dysfunction observed in both syndromes.
Introduction
. Increased plasma concentrations of endogenous arginine analogues such as L-NMMA, symmetric Chronic renal and heart failure are accompanied by and asymmetric dimethylarginine (SDMA and ADMA, endothelial dysfunction and there is controversy as to respectively) together with reduced arginine levels may in whether systemic production of nitric oxide (NO) is part explain impaired responses to NO in patients with increased in these disease states [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , since some reports chronic renal or heart failure [25, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Transport of do not confirm these findings [20] [21] [22] [23] [24] [25] [26] [27] . The prolonged L-arginine (precursor of NO) is elevated in red blood cells bleeding time in patients with chronic renal failure and peripheral blood mononuclear cells [40] [41] [42] [43] [44] , sug-(uraemia) may be the consequence of increased NO gesting that uraemia and heart failure induce adaptive synthesis, since in animal models this altered coagulation increases in the activity of the cationic amino acid trans- Moreover, plasma concentrations of nitrates are elevated in system y L; the observed activation of this system in patients with chronic renal failure, further supporting the uraemic platelets may be crucial to the enhanced synthesis hypothesis that NO production is up-regulated in uraemia of NO by these cells observed in renal failure [45] . This review examines the mechanisms underlying alterations in NO production in chronic renal and heart failure, and considers the evidence, based on studies in circulating reviewed in detail [69] . L-Arginine is involved in the blood cells, that elevated cytokine levels and altered synthesis of proteins, creatinine, urea, agmatime and substrate availability due to diminished plasma L-arginine polyamines and modulates the delivery of hormones and and increased L-arginine analogues levels activate the L- the synthesis of pyrimidine bases [70] . L-Arginine proarginine-NO signalling pathway in circulating blood cells duced by the liver is metabolised locally and does not and most likely vascular cells.
contribute significantly to circulating plasma L-arginine levels (80-120 mmol / l), which are mainly dependent on dietary intake of L-arginine (1-2 g / day) and synthesis by 2. L-Arginine transport in circulating blood cells the proximal tubule of the kidney. In humans, the conversion of L-citrulline to L-arginine is independent of the Membrane transport of cationic amino acids, initially intake of L-arginine or protein [70] , but in disease states, 1 1 assigned to the classical Na -independent system y [46] , where synthesis of L-arginine is decreased and catabolism has now been shown to be mediated by at least five increased, L-arginine may become an essential amino acid and systems b and B (broad specificity for neutral family of NO synthases: neuronal NOS (nNOS), endotheliand cationic amino acids). The murine and human isoforms al NOS (eNOS), and inducible NOS (iNOS, from activated of CAT-2A and CAT-2B differ only in a stretch of 42 macrophages) [71] [72] [73] . L-Arginine augments collagen-inamino acids and are likely to be the product of differently duced increases in platelet cyclic GMP levels and inhibits spliced mRNAs [53] [54] [55] [56] . Transport of arginine, lysine and platelet aggregation, suggesting that L-arginine transport 1 ornithine via system y (CAT-1) is relatively pH-inand NO production may be coupled [74] . NO may also dependent, sensitive to trans-stimulation and saturable at react directly with oxyhaemoglobin forming nitrate and circulating plasma concentrations (|0.1-0.2 mM). System metahaemoglobin, and with haemoglobin to form nitro-1 y is also sensitive to changes in membrane potential sylhaemoglobin [75] . Thus, red blood cells can inactivate [57] [58] [59] [60] , with hyperpolarization increasing cationic amino NO under conditions where NO-mediated vasodilatation is acid transport influx. A new member of the CAT family undesired such as haemorrhage [76] . Recent evidence (rCAT3) has recently been isolated from rat brain and suggests that erythrocytes can release NO bound to haemo-1 expresses y transport activity [61] . Unlike the other CAT globin in the microcirculation under low oxygen tension isoforms, transport properties of a newly identified CAT-4
[77]. Although human erythrocytes appear to express both isoform have yet to be described in detail [62] .
iNOS and eNOS [78] [79] [80] , further studies are necessary to L-Arginine transport in red blood cells and peripheral substantiate these claims. Nevertheless, red blood cells are blood mononuclear cells is mediated via the cationic amino capable of producing NO from nitrovasodilators such as ters (y LAT1 and y LAT2) have been identified and it human urine infected with bacteria express active iNOS 1 1 seems that y LAT and 4F2hc combine to induce y L localised to the membrane fraction of leukocytes [84] .
0,1 0,1 1 transport activity [65] [66] [67] . Systems B and b (NaNon-activated human monocytes / macrophages express 1 dependent and Na -independent isoforms, respectively) eNOS and iNOS at rest or following stimulation, respecinitially described in early mouse embryos [47, 50, 51, 68] tively [82, 85, 86] . Constitutive, low levels of iNOS have have not been described in human red blood cells or been detected in Epstein-Barr virus transformed human B peripheral blood mononuclear cells.
lymphocytes, and the inhibition of apoptosis by NO is largely independent of cGMP and mediated by the cellular redox status [87] . Platelets express both constitutive and 3. L-Arginine transport and nitric oxide production inducible forms of NO synthase [74, 88, 89] , and iNOS activity is induced within 30 min and is maximal 2 h after 3.1. Synthesis and metabolism of arginine stimulation with LPS and cytokines [88] .
1
In several cell types, NOS and the y / CAT transport Metabolism of arginine by mammalian cells has been system seem to be regulated in parallel. L-Lysine, a competitive inhibitor of L-arginine transport, inhibits NO plasma L-arginine levels and elevated L-NMMA, SDMA production in rat cardiac myocytes exposed to cytokines and ADMA levels, as reported in heart and renal failure, [52] . In rat astrocytes there is evidence of a coordinated intracellular supply of L-arginine may be limited due to regulation of iNOS and L-arginine transport [90] . Treatlow substrate availability and competition for transport. We ment of endothelial or smooth muscle cells with cytokines also have shown that the transport of L-arginine via system 1 induces iNOS and increases the expression of mRNA for y L in human platelets is up-regulated in uraemia [45] . CAT-1 and CAT-2B L-arginine transporters [91] [92] [93] [94] [95] .
Recently, we have demonstrated that, in platelets, inhibi-
However, there are reports of independent mechanisms tion of L-arginine transport via y L system by both neutral regulating the transcription of CAT transporters and iNOS and cationic amino acids inhibits NO platelet synthesis in endothelial and smooth muscle cells [93] [94] [95] and (unpublished data). This activation of transport may promacrophages [96] . Dexamethasone inhibits the transcripvide a mechanism whereby uraemic platelets maintain their tion of L-arginine transporters, and it has been suggested production of NO in spite of the reduced plasma availabilithat glucocorticoids may modulate NO synthesis partially ty of L-arginine. Moreover, synthesis of NO by uraemic by limiting intracellular L-arginine availability [92, 96] .
platelets may provide a protective mechanism against Insulin has been shown to up-regulate NO production and increased aggregation and accelerated atherosclerosis L-arginine transport via CAT-1 in human endothelial cells characteristic of renal failure. and cardiac myocytes [52, 97] . Moreover, in activated rat
The gastric hyperaemia and increased susceptibility to macrophages, induction of L-arginine transport is required gastric lesions observed in chronic renal failure patients to sustain elevated NO synthesis [96, 98] .
may be related to an enhanced synthesis of NO, since gastric blood flow, in a rat model of uraemia, returns to normal after the administration of nitro-L-arginine methyl 4. Modulation of the L-arginine-NO pathway in ester (L-NAME) [114, 115] . Nevertheless, it is worth noting chronic renal failure that a decreased expression of eNOS has been detected in the gastric mucosa of uraemic rats [116] . Accumulation of The alterations in blood pressure observed in chronic nitrates in peripheral blood from uraemic patients on renal failure patients seem to be partially related to a haemodialysis is increased compared to controls dysfunction in the modulation of the L-arginine-NO [4, 6, 12, 14, 18] . This increase in NO production is related to signalling pathway in the vasculature of animals models the type of dialysis membrane used in treatment and has and uraemic patients (see Tables 1 and 2 ) [99] . Indeed, been reported more frequently in patients who present with chronic renal failure patients exhibit endothelial cell hypotension during dialysis [4-6,12-14]. damage, and an impairment in endothelium-dependent Although upregulation of vascular NOS activity is a relaxation, that presents in very early stages of the homeostatic adaptation to prevent kidney damage [117], syndrome [100] [101] [102] [103] [104] [105] , although these findings do not seem the production of NO by the kidney seems to be reduced in to be present in rat models of uraemia [106, 107] . This chronic renal failure [110] [111] [112] . In rats, inhibition of NO endothelial dysfunction seems to be reversed by infusion production leads to systemic hypertension, a diminution of of L-arginine and renal dialysis [105] .
the glomerular filtration rate and, if the inhibition persists, NO is one of the key regulators of renal haemodynamics uraemia [118] [119] [120] [121] . Administration of L-arginine in animal and in the kidney NO is produced by endothelial, mesangimodels improves kidney function in several conditions al and inflammatory cells [108] [109] [110] [111] . The status of NO in known to lead to chronic renal failure, such as obstructive chronic renal failure is complex with indirect evidence nephropathy, hypertension, partial renal ablation and diasuggesting that NO production is increased [1,4-9,12- betes mellitus [70] . Recent studies have further demon-14, 16, 18] . The prolonged bleeding time observed in pastrated that formation of NO and expression of iNOS are tients with chronic renal failure appears to be reversed in reduced in parallel in uraemic renal tissue from rats, uraemic rats following infusion of the NOS inhibitor, whereas the activity and expression of eNOS and iNOS L-NMMA [1, 28] . Moreover, the systemic production of appear to be up-regulated in the systemic vasculature NO based on the concentration of nitrites / nitrates in [112] . plasma seems to be increased in uraemic rats [110, 112] .
A guanidino analogue of L-arginine (asymmetric diPlatelets from uraemic patients synthesise more NO than methyl arginine) was reported to be increased in uraemic control cells [1] , and uraemic plasma increases the proplasma, and these authors suggested that inhibition of NO duction of NO by endothelial cells [1] . Interestingly, synthesis contributed to the hypertension and immune platelets from uraemic patients seem to have a diminished dysfunction observed in chronic renal failure [29] [30] [31] [32] [33] [34] [35] 37 response to NO, implying that NO synthesis in these cells 39] . As summarised in Table 3 , we have reported that may already be up-regulated [113] .
plasma levels of L-arginine are reduced significantly in Recently, we have demonstrated that the transport of uraemic subjects predialysis, whilst plasma levels of L-L-arginine in platelets is mediated by the high affinity citrulline were increased [31] . We have also demonstrated 1 system y L [45] . The very low K of this system (|10 that plasma levels of L-arginine correlated with renal M mM) suggests that under conditions of low circulating function indexes in undialysed patients with chronic renal failure ( Fig. 1; unpublished data) . There are several studies of plasma amino acid levels in uraemic patients, which have reported increased, unaltered or decreased levels of L-arginine [122] [123] [124] [125] [126] [127] [128] . However, it is clear that in uraemia the total amino acid pool is depleted and that L-arginine may become an essential amino acid in this pathological state [70] .
The activity of a large number of other membrane transporters is also altered in erythrocytes from uraemic Mendes Ribeiro et al. [42] . secondary to partial nephrectomy present with unaltered the bleeding time is significantly reduced in mice lacking plasma L-arginine levels compared to controls and under platelet eNOS compared to mice with normal platelets these conditions transport of L-arginine and L-lysine in [134] . The same group has also shown that platelets from brain microvessels and red blood cells is unaffected patients with acute coronary syndromes produce less NO, [132, 133] . These findings further support the hypothesis suggesting that impaired platelet-derived NO production that decreased plasma L-arginine levels may trigger upmay contribute to thrombus formation in these syndromes regulation of L-arginine transport observed in human [135] . circulating blood cells [40, 42] .
Recently, we demonstrated that L-arginine transport in
Platelet function is partially mediated by endogenous platelets is solely mediated by system y L, which is production of NO by platelets and previous studies have up-regulated in platelets from chronic renal failure patients demonstrated that uraemic platelets generate more NO than in dialysis [45] (Fig. 6 ). Since the transport of L-arginine 1 1 Fig. 4 . Comparison of the initial rate of L-arginine influx (2 mM) via systems y and y L in human peripheral blood mononuclear cells from control (n510) and uraemic patients: continuous ambulatory peritoneal dialysis (n56), pre-haemodialysis (n510) and post-haemodialysis (3-4 h, n510). Data denote the mean6S.E. Replotted from Mendes Ribeiro et al. [43, 44] .
thesis. The activation of L-arginine uptake in uraemic platelets is most probably involved in haemostatic alterations in this syndrome and may also be protective against atherothrombosis.
Modulation of the L-arginine-NO pathway in chronic heart failure
Heart failure is a complex clinical syndrome broadly defined as a condition in which cardiac output is insufficient to maintain adequate perfusion of tissues [136] . The endothelium-dependent dilatation of arteries [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] , but not the microvasculature [151] , is impaired and related to the clinical severity of heart failure. NO synthase is expressed constitutively in the vascular endothelium, cardiac conduction tissue and myocytes [139] , and iNOS has been detected in endothelium, infiltrating inflammatory cells, vascular smooth cells and myocytes in the presence of cytokines [139, [152] [153] [154] [155] [156] [157] [158] . Recent evidence suggests that endothelial dysfunction could result from a decreased release or enhanced activation of NO [157] [158] [159] [160] (see Tables 4 and 5 ). Clinical and experimental studies have reported increased plasma levels of the L-arginine analogue, ADMA, which could impair endothelium-dependent relaxation [11, 36] . In contrast, several clinical studies have demonstrated that patients with heart failure exhibit an increased responsiveness to inhibitors of NO synthesis and elevated plasma levels of stable NO breakdown products [2,3,10,15], suggesting that NO synthesis is increased rather than decreased. Thus, increased release of NO in 1 chronic heart failure may represent another failing counter- direct evidence for increased synthesis of NO, and blood flow responses to endothelium-independent vasodilators such as nitroglycerin are preserved [139] . It seems that NO synthesis and activity are abnormal in patients with heart failure, with the release of NO increased in heart conductance vessels although endothelium-dependent responses are blunted [139] . Increased oxidative stress and reduced antioxidant reserve have been demonstrated in heart failure subjects which can accelerated the inactivation of NO [161] [162] [163] [164] [165] . It is interesting to note that the antioxidant vitamin ascorbic acid improves endothelium-dependent relaxation in patients with heart failure [165] . The efficacy of oral L-arginine supplementation in endothelial function in heart failure remains controversial [166] [167] [168] . In the heart, NO has negative inotropic effects and plays a role in morphologic alterations such as hypertrophy and apoptosis on cardiomyocytes [152] [153] [154] [155] [156] 170, [174] [175] [176] [177] or n58) and chronic renal failure patients on haemodialysis (j, n510). Data denote the mean6S.E. Taken from Mendes Ribeiro et al. [45] .
both [178] in the failing myocardium. The putative de- exercise partially restores flow-mediated dilation by increasing eNOS a ADMA; assymetric dimethyl-L-arginine; cGMP, cyclic guanosine monophosphate; NO, nitric oxide; NOS, nitric oxide synthase; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase; NO, nitric oxide, sGC, soluble guanylate cyclase, CHF, chronic heart failure. 1 leterious actions of the negative inotropic effect of NO on system y / CAT [40, 41] (see Fig. 7 ). We have also ventricular contractility is counter-balanced by a reduction reported that plasma concentrations of L-arginine are in myocardial oxygen consumption and enhanced coronary reduced in chronic heart failure patients (see Table 3 and blood flow, preventing deterioration in myocardial perRef. [40] ). Our findings demonstrate a reduced supply of formance [179] . Recently, it has been reported that an endogenous L-arginine which are consistent with reports of increase in endomyocardial iNOS and eNOS expression an improvement of blood flow and clinical conditions in augments cardiac output in patients with dilated carchronic heart failure patients following L-arginine supplediomyopathy [180] . It has been suggested that in chronic mentation [182] . heart failure increased plasma levels of circulating cytokines, especially TNF-a, may be responsible for a blunted 1 endothelial response to agonists such as acetylcholine via a 6. Activation of system y in uraemia and heart direct impairment of NO release, and destabilising of failure: a failing counter-regulatory mechanism endothelial NOS mRNA levels [181] . At the same time, cytokines will induce iNOS and thereby NO release [153] .
The fact that a similar increase in transport capacity for In this context, IL1-b and interferon-g pretreated myocytes L-arginine was observed in chronic renal and heart failure, express both iNOS and CAT transporters for L-arginine syndromes with a very different aetiology, argues against a [52] . specific effect of a uraemic toxin. In both chronic renal and We have reported that erythrocytes and peripheral blood heart failure, increased concentrations of circulating cytomononuclear cells from chronic heart failure patients kines (IL-1, IL-6, TNF-a) may induce the expression of exhibit an increased transport capacity for arginine via CAT-2 transporters and / or iNOS in peripheral mononu- synthase; system y / CAT, Na -independent cationic amino acid transporter, PBMCs, peripheral blood mononuclear cells.
hypertension in uraemia may be explained partially by an insufficient availability of L-arginine for eNOS in endothelial cells. The increase of L-arginine influx in red blood cells and peripheral mononuclear cells observed in chronic renal and heart failure may be associated with low plasma L-arginine. Indeed limited L-arginine availability has been reported to up-regulate L-arginine transport in endothelial 1 cells via system y [60] and amino acid starvation has been reported to increase CAT-1 mRNA 3-fold in Fao cells [183] .
Summary
In both chronic renal and heart failure, endotheliumdependent relaxation is impaired whilst it seems likely that there is an increased systemic production of NO. If the up-regulation of L-arginine membrane transport in blood cells reported by our group is present in other cell types and tissues, this may provide a mechanism by which vascular cells compensate for the reduced vascular pool of L-arginine in uraemia and heart failure. The endothelial dysfunction present in both chronic renal and heart failure and its reversal by L-arginine supplementation may be of relevance to atherogenesis and hypertension in chronic renal failure and the widespread vasoconstriction observed in chronic heart failure. The observed low L-arginine and elevated arginine analogue plasma concentrations coupled with increased levels of cytokines and NO production would lead to up-regulation of L-arginine transport. Never- NO production appears to be a failing counter-regulatory denote the mean6S.E. Replotted from Hanssen et al. [40] .
mechanism in both chronic renal and heart failure.
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It is also possible that the same adaptive mechanism is widespread vasoconstriction in chronic heart failure and 
